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y-Seminoprotein (y-Sm) is a human prostate-specific antigen and a serine protease judging from the com- 
plete amino acid sequence which shows extensive homology with the kallikrein family. The enzymatic activi- 
ty of y-Sm was defined as a chymotypsin-like activity using reduced and S-3-(trimethylated amino)propylat- 
ed lysozyme and insulin-oxidized A and B chains as substrates. The -Le&er- peptide bond of lysozyme 
was rapidly hydrolyzed by y-Sm. y-Sm also hydrolyzed the -PheLGlu- of lysozyme and the -Le&ys(SO,H)- 
of insulin B chain. Insulin A chain and arginyl- or lysyl-linkage of these proteins were not hydrolyzed by 
y-Sm at all. 
Prostate-specific antigen; Seminal plasma protease; Chymotrypsin-like enzyme; y-Seminoprotein 
1. INTRODUCTION 
y-Seminoprotein, a major seminal-specific an- 
tigen, is a glycoprotein isolated from human 
seminal plasma [l]. The complete amino acid se- 
quence (237 residues) of y-Sm [2,3] has been 
recently determined using protein chemical 
methods. Sequence comparison of y-Sm with 
serine proteases shows a high degree of homology, 
especially with the kallikrein family. Although the 
biological function of y-Sm has not been estab- 
lished, the utility of y-Sm has been shown in 
forensic medicine to identify seminal stain [4] as 
well as in the diagnosis and monitoring of prostate 
cancer [5]. 
During these studies, Lundwall and Lilja [6] 
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have also presented the amino acid sequence of a 
human prostate-specific antigen (PSA) deduced 
from a cDNA clone which is identical to that of y- 
Sm [3]. The primary structure of the prostate- 
specific antigen (PA) presented by Watt et al. [7] 
is also very similar to those of y-Sm and PSA. Of 
these antigens, PA displays low but detectable ac- 
tivity towards not only chymotryptic but also tryp- 
tic substrates [7], and PSA displays no detectable 
activity against N-benzoyl-tyrosine ethyl ester but 
against Arg/Lys containing substrates [8]. The 
substrate specificity of prostate-specific antigen 
has been so obscure and there are no clear ex- 
perimental data which can define the cleavage sites 
of protein substrates by the prostate-specific an- 
tigen. Here we describe the cleavage sites of re- 
duced and S-3-(trimethylated amino)propylated 
lysozyme and insulin-oxidized B chain by y-Sm. 
2. MATERIALS AND METHODS 
y-Sm prepared from human seminal plasma [3] 
was passed through a benzamidine-Sepharose 6B 
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column (Sigma, 2 ml) with 0.1 M ammonium 
bicarbonate containing 1 M guanidine-HCl, pH 
8.0. The unbound fraction was used as y-Sm in this 
experiment. RSA-lysozyme [9] and insulin- 
oxidized A and B chains (Sigma) were used as pro- 
tein substrates. The substrate (1 mg) dissolved in 
300~1 of 0.05 M Tris-HCI buffer, pH 8.0, was in- 
cubated with y-Sm (1Opg) at 37°C. After 60 min, 
the digest was subjected to reverse-phase high per- 
formance liquid chromatography (HPLC) to 
separate peptides by a Beckman HPLC system (see 
legend to fig.lA). For an examination of the time 
course of digestion, an aliquot of the digest of 
RSA-lysozyme was removed after 10, 60 and 
120 min incubations and followed by SDS- 
polyacrylamide gel electrophoresis (PAGE) [lo]. 
The rate of hydrolysis of Suc-Ala-Ala-Pro-Phe- 
pNA (1 mM) and Sue-Ala-Ala-Pro-Leu-pNA 
(1 mM) (Bachem, Feinchemikalien AG) was 
measured spectrophotometrically at 405 nm after 
incubation with y-Sm (10 pg) in 250 ~1 of 0.1 M 
Tris-HCl buffer, pH 8.0, at 37°C for 60 min 
followed by adding 800 ~1 of 0.6 M acetic acid. 
An aliquot (100 ~1) from fractions of the 
reverse-phase HPLC was hydrolyzed in 5.7 M HCl 
at 110°C for 20 h. The hydrolysates were analyzed 
by the phenylthiocarbamyl method on a Pica Tag 
system (Waters, Millipore Corp., Milford, MA), in 
conformity with the operator’s manual. Approx. 
5 nmol each of the fragments derived from the 
60 min-digest of RSA-lysozyme was analyzed on 
their NHZ-terminal sequences by manual Edman 
degradation according to the film method [ll]. 
The PTH amino acids were identified by HPLC on 
a Zorbax CN column (4.6 x 250 mm) with a ter- 
nary gradient system [12]. 
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Fig.1. Analyses of the digests of RSA-lysozyme with y-Sm. (A) Reverse-phase HPLC of the digest (60 min) on a 
Cosmosile 5C18P column (10 x 250 mm) at a flow rate of 0.5 ml/min. Elution was performed with an 80 min gradient 
from 0 to 30% solvent B; solvent A, 0.1% (v/v) trifluoroacetic acid in water; solvent B, 0.1% (v/v) trifluoroacetic acid 
in acetonitrile. (B) SDS-PAGE (12% polyacrylamide gel with 8 M urea) of the digests at 10, 60 and 120 min. (a) 
Control; (b) digests; (c) molecular mass markers (Fluka AC). 
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3. RESULTS sequence analysis (table 2). L-l was assigned as the 
NH2-terminal fragment from Lys-1 to Tyr-23. 
The time course of hydrolysis of RSA-lysozyme On the other hand, insulin-oxidized B chain 
by y-Sm is shown by the patterns of SDS-PAGE of digested by y-Sm was separated into four 
the digests (fig.lB). The peptide fragments of the fragments (I-l, I-2, I-3 and I-4) by reverse-phase 
60 min-digest were separated by reverse-phase HPLC (not shown). The yields of these fragments 
HPLC (fig. 1A). The amino acid compositions and were 14% for I-l and I-4 and 2% for I-2 and I-3 
NHz-terminal sequences of these fragments are which were deduced to be generated by a cleavage 
shown in tables 1 and 2. Comparing these data of -Leu-6kys[SOsH]-7-, and of -Tyr-16LLeu-17-, 
with the sequence of lysozyme [ 131, the position of respectively, based on their amino acid composi- 
each fragment at the parent sequence was de- tions (not shown). The HPLC chromatogram of 
duced. The fragments L-3 and L-4 corresponded the digested insulin-oxidized A chain showed the 
respectively to the COOH-terminal portion same pattern as that of the undigested sample. The 
(Ser-85-Leu-129) and to the NHz-terminal portion rate of hydrolysis of Sue-Ala-Ala-Pro-Phe-pNA 
(Lys-1-Leu-84) of lysozyme. Although the amino and Sue-Ala-Ala-Pro-Leu-pNA by y-Sm was 
acid composition of L-2 corresponded to that of calculated to be 2.10 and 1.05 pM/min per mg, 
the NHz-terminal to Leu-84, this fragment was respectively. However, these values were about 
found to be composed of two fragments ‘(Lys-l- 4000-times and lOOO-times less than those of LY- 
Phe-34 and Glu-35-Leu-84) by the NHz-terminal chymotrypsin, respectively. 
Table 1 
Amino acid compositions of four fragments obtained from the digest of RSA- 
lysozyme with y-Sm 
Amino 
acid 
L-l 
Residues per molecule 
L-2 L-3 L-4 
RSA- 
lysozyme 
Asp 2.2(2) 15.5(14) 7.0(7) 15.8(14) (21) 
Thr 5.1(5) 2.0(2) 5.3(5) (7) 
Ser 5.7(6) 3.2(4) 5.9(6) (10) 
GIU 1.4(l) 4.2(4) 1.2(l) 4.2(4) (5) 
Pro 2.0(2) 2.0(2) (2) 
GlY 4.1(3) 8.3(8) 3.6(4) 8.1(8) (12) 
Ala 3.2(3) 7.7(7) 4.6(5) 7.4(7) (12) 
cys/2 (1) (5) (3) (5) (8) 
Val 1.2(l) 2.4(2) 2.8(4) 2.2(2) (6) 
Met 0.6( 1) 0.5(l) 0.4(l) 0.5(l) (2) 
Ile 3.0(3) 2.1(3) 3.2(3) (6) 
Leu 2.0(2) 6.8(7) 1.4(l) 6.6(7) (8) 
TYr 1.8(2) 2.7(3) 0.2 2.5(3) (3) 
Phe 1.0(l) 2.7(3) 0.2 2.6(3) (3) 
LYs 1.9(2) 3.3(3) 2.4(3) 3.1(3) (6) 
His 1.2(l) 1.0(l) 0.9(l) (1) 
Trp (3) (3) (3) (6) 
Arg 4.2(3) 8.2(7) 3.9(4) 7.8(7) (11) 
Total (23) (84) (45) (84) (129) 
Position l-23 l-34, 85-129 l-84 
35-84 
Yield (clro) 2.5 32.5 40.0 16.2 
Values in parentheses are taken from the sequence data [13] 
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Table 2 
NHz-terminal sequences of four fragments obtained from the 
digest of RSA-lysozyme with y-Sm 
December 1987 
Cycle 
no. 
L-l L-2 L-3 L-4 
1 L~s(N.Q.)~ Glu(l.26) Ser(N.Q.) Lys(O.5 1) 
2 Val(l.10) Xb Ser(N.Q.) Val(1.19) 
3 Phe(1.38) Asn(0.88) Asp(0.24) Phe(0.45) 
4 Gly(0.40) Phe( 1.76) Ile(0.24) Gly( 1.09) 
5 Arg(0.25) Asn(0.61) X Arg(0.65) 
a Not quantitated 
b Not identified 
Approx. 5 nmol each of the samples was applied to the 
sequence analysis. Values in parentheses are approximate yields 
(nmol) of phenyl-thiohydantoin derivatives calculated from 
peak areas on HPLC 
4. DISCUSSION 
Based on the primary structure, y-Sm is a serine 
protease showing the conservation of residues 
(His-41, Asp-96 and Ser-189) in the vicinity of the 
active site of serine proteases [3] and a homology 
(62%) with human pancreatic kallikrein [14]. 
Comparing residue 183 at the bottom of the 
substrate binding pocket of y-Sm with that of pan- 
creatic kallikrein, this position is occupied in y-Sm 
by a Ser residue and by an Asp residue in 
kallikrein. However, PA and PSA which seem 
likely to be the same enzyme as y-Sm have been 
reported to express trypsin- and chymotrypsin-like 
specificities toward insulin A and B chains and 
recombinant interleukin 2 [7,8]. 
In this experiment, y-Sm was further purified 
through a benzamidine-Sepharose column to ex- 
elude contamination, if present, responsible for 
trypsin-like activity. The cleavage sites of RSA- 
Table 3 
Cleavage sites of RSA-lysozyme and insulin-oxidized B chain by y-Sm 
P4 P3 P2 PI Pl’P2’P3’ P4’ Rate of 
hydrolysis” 
RSA-lysozyme -Ser-Ala-Leu-Leu-her-Ser-Asp-Ile- rapid 
-Ala-Ala-Lys-Phe-blu-Ser-Asn-Phe- rapid 
-Tyr-Arg-Gly-Tyr-ker-Leu-Gly-Asn- very slow 
Insulin- -Asn-Gln-His-Leu-kysb-Gly-Ser-His- rapid 
oxidized 
B chain -Glu-Ala-Leu-TyriLeu-Val-Cysb-Gly- very slow 
a Based on the yield of the fragments generated after digestion for 
60 min 
b Cys(S03H) 
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lysozyme and insulin-oxidized B chain by y-Sm are 
listed with their subsites in table 3. The Leu-84L 
Ser-85 bond of RSA-lysozyme was found to be the 
most susceptible linkage. The Phe-34LGlu-35 of 
RSA-lysozyme and Leu-6LCys(S03H)-7 of insulin- 
oxidized B chain were also hydrolyzed by y-Sm. 
The T r-23&Ser-24 of RSA-lysozyme and the 
Tyr-16 r Leu-17 of insulin-oxidized B chain were 
hydrolyzed slightly after 1 h incubation. Except 
for these bonds, neither the Leu-X (X = Ala, Val, 
Tyr, Gly, Gln, Asp or Cys-alkylated), the Phe-Y 
(Y =Phe, Tyr, Val, Asn or Gly), the Tyr-Z 
(Z=Arg, Gln, Gly, Thr or Cys(SO3H)), lysyl nor 
arginyl bonds present in RSA-lysozyme, insulin- 
oxidized A chain or B chain were hydrolyzed by y- 
Sm. Therefore, the data presented here indicate 
that the enzymatic activity of y-Sm is defined as a 
chymotrypsin-like activity with strict substrate 
specificity. Leucyl, phenylalanyl and tyrosyl bonds 
followed by a suitable amino acid as the subsite of 
Pl ’ are concerned with the substrate specificity of 
y-Sm (table 3). Also, the subsites of P3, P2 and 
P2’ may have some role in the specificity of r-Sm, 
though any definite amino acid cannot be stated at 
present. Investigation of the physiological 
substrate for y-Sm will be followed. 
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